Pfizer Lays Out A Growth Plan To Offset $17bn In Coming Exclusivity Losses
Management presented a strategy for establishing new blockbuster brands in migraine, RSV, inflammatory bowel disease, cancer and diabetes/obesity during an investor day.
You may also be interested in...
Chief development officer William Pao will depart the company in a sudden transition after being recruited from Roche. Pfizer insiders Chris Boshoff and Mikael Dolsten will fill the roles.
The company presented data for its MenABCWY vaccine, but it still hasn’t specified the timing for approval. While its launch would lag Pfizer’s, GSK has an advantage in terms of data as well as leadership in the space.
Pfizer and Astellas announced positive topline Phase III results in non-metastatic prostate cancer for Xtandi, one of the top-selling drugs in Pfizer’s portfolio set to lose patent exclusivity this decade.